Pharsight

Upjohn patents expiration

1. Lyrica Cr patents expiration

LYRICA CR's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10022447 UPJOHN Solid pharmaceutical compositions containing pregabalin
Nov, 2026

(3 years from now)

US8945620 UPJOHN Solid pharmaceutical compositions containing pregabalin
Nov, 2026

(3 years from now)

US9144559 UPJOHN Solid pharmaceutical compositions containing pregabalin
Nov, 2026

(3 years from now)

US9144559

(Pediatric)

UPJOHN Solid pharmaceutical compositions containing pregabalin
May, 2027

(3 years from now)

US10022447

(Pediatric)

UPJOHN Solid pharmaceutical compositions containing pregabalin
May, 2027

(3 years from now)

US8945620

(Pediatric)

UPJOHN Solid pharmaceutical compositions containing pregabalin
May, 2027

(3 years from now)

Drugs and Companies using PREGABALIN ingredient

Market Authorisation Date: 11 October, 2017

Treatment: Treatment of postherpetic neuralgia; Treatment of neuropathic pain associated with diabetic peripheral neuropathy

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of LYRICA CR before it's drug patent expiration?
More Information on Dosage

LYRICA CR family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic